A Phase 1 interventional study of MK-8808 and cyclophosphamide in Follicular Lymphoma, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.
Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 166th largest by enrollment of the 188 interventional ones that give a count, is one of 9 that started in 2011, is one of 27 in phase 1, and was the 132nd registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 129 · Phase 3 37
First in 1997; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 48 across the 188 interventional studies. Of the 150 that completed or were terminated, 75 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 194 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 9 studies filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
5 of the studies testing rituximab in Lymphoma, Follicular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04224493Phase 3Epizyme, Inc.A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | 2027-02-13 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT06471738Chinese PLA General HospitalCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | 2026-12-30 |
| NCT01473628M.D. Anderson Cancer CenterRadiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma | 2027-05-20 |
| NCT04998669Juan P. Alderuccio, MDLoncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 194 studies testing rituximab in Lymphoma, Follicular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, pharmacokinetics, and anti-tumor activity of MK-8808 in combination with cyclophosphamide, vincristine, and prednisolone (CVP), and as a single agent, for participants with B-lymphocyte antigen cluster of differentiation 20 (CD20)-positive follicular lymphoma who have had no prior chemotherapy. The primary study hypothesis is that MK-8808 will be safe and well tolerated in combination with CVP and as a single agent.
The study was terminated early by the Sponsor due to business reasons. All participants were discontinued from MK-8808 + CVP, but could continue to receive maintenance therapy with MabThera™ (rituximab) per standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Has one of the following:
Has one or more of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received MK-8808 375 mg/m\^2 intravenously (IV) + cyclophosphamide 750 mg/m\^2 IV + vincristine 1.4 mg/m\^2 IV (maximum dose of 2 mg IV) on Day 1 each cycle, plus prednisolone 40 mg/m\^2, orally on Days 1 to 5 of each cycle for a maximum of 8 cycles. Participants receiving clinical benefit could remain on MK-8808 375 mg/m\^2 IV starting 8 weeks after last dose of combination therapy, every 2 months for up to 2 years.
Drug: MK-8808 · Drug: cyclophosphamide · Drug: vincristine · Drug: prednisolone
Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy
An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
Time frame: From first dose of combination therapy up to 24 weeks
Number of Participants Experiencing Clinical and Laboratory AEs During MK-8808 Maintenance Therapy
An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
Time frame: From first dose of single agent MK-8808 up to 2 years
Maximum Concentration (Cmax) of Plasma Levels of MK-8808 When Used in Combination With CVP
Cmax is a measure of the maximum concentration of the drug in the plasma as measured using plasma samples taken over specified time points.
Time frame: Pre-dose and end of infusion in each 21-day cycle and at end of therapy visit (up to 24 weeks)
Cmax of Plasma Levels of MK-8808 During Single Agent Maintenance Therapy
Cmax is a measure of the maximum amount of drug in the plasma over time using samples taken at specified time points.
Time frame: Predose and end of infusion in every other cycle and at end of therapy visit (up to 2 years)
Lowest Concentration (Ctrough) of Plasma Levels of MK-8808 When Used in Combination With CVP
Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.
Time frame: Pre-dose and end of infusion in each 21-day cycle and at end of therapy visit (up to 24 weeks)
Ctrough of Plasma Levels of MK-8808 When Used as Single Agent Maintenance
Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.
Time frame: Predose and end of infusion in every other cycle and at end of therapy visit (up to 2 years)
Clinical Response of Tumor to MK-8808/CVP Combination Therapy
The response of the tumor to MK-8808/CVP combination therapy was radiographically assessed using Response Criteria Evaluation in Solid Tumors (RECIST). Response categories of partial response (PR), complete resonse (CR), and uncomfirmed (CRu) central review.
Time frame: Up to 2 years
The study was terminated early by the Sponsor due to business reasons. All participants were discontinued from MK-8808 on 18 March 2014, but could continue to receive maintenance therapy with rituximab per standard of care.
| Milestone | MK-8808 Combination Therapy |
|---|---|
| Started | 7 |
| Completed | 1 |
| Not completed | 6 |
| Withdrew: Switched to rituximab | 4 |
| Withdrew: Progressive disease | 2 |
An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
| Participants | MK-8808 Combination Therapy |
|---|---|
| Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy | 6 |
An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
No measurements were reported for this outcome.
Cmax is a measure of the maximum concentration of the drug in the plasma as measured using plasma samples taken over specified time points.
No measurements were reported for this outcome.
Cmax is a measure of the maximum amount of drug in the plasma over time using samples taken at specified time points.
No measurements were reported for this outcome.
Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.
No measurements were reported for this outcome.
Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.
No measurements were reported for this outcome.
The response of the tumor to MK-8808/CVP combination therapy was radiographically assessed using Response Criteria Evaluation in Solid Tumors (RECIST). Response categories of partial response (PR), complete resonse (CR), and uncomfirmed (CRu) central review.
| Participants | MK-8808 Combination Therapy |
|---|---|
| PR | 6 |
| CR | 0 |
| CRu | 0 |
Collected over Up to 30 days after last dose of CVP therapy (up to 28 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-8808 Combination Therapy | — | 1/7 (14.3%) | 6/7 (85.7%) |
| Event | MK-8808 Combination Therapy |
|---|---|
| Femoral neck fractureInjury, poisoning and procedural complications | 1/7 |
| Event | MK-8808 Combination Therapy |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/7 |
| TachycardiaCardiac disorders | 1/7 |
| BlepharitisEye disorders | 1/7 |
| HypersensitivityImmune system disorders | 1/7 |
| BronchitisInfections and infestations | 1/7 |
| GastroenteritisInfections and infestations | 1/7 |
| PharyngotonsillitisInfections and infestations | 1/7 |
| Skin infectionInfections and infestations | 1/7 |
| Upper respiratory tract infectionInfections and infestations | 1/7 |
| Alanine aminotransferase increasedInvestigations | 1/7 |
| Age, Continuous(Years) | MK-8808 Combination Therapy |
|---|---|
| Mean | 56.1 ± 16.4 |
| Sex: Female, Male(Participants) | MK-8808 Combination Therapy |
|---|---|
| Female | 2 |
| Male | 5 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Aug 2011 to primary completion in Dec 2014, 39 months.
Results were first posted in Nov 2015, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab